Teleflex Incorporated [TFX] stock has had a turbulent period. The stock touched a 52-week low several times amidst market shifts and challenges. Overall performance has been under scrutiny, with Zacks Research showing concern over the Q4 earnings and the firm's performance in comparison to the wider healthcare sector. Despite this, TFX has seen some stock gains with JPMorgan Chase & Co, Assenagon Asset Management, and Oak Thistle LLC increasing stake. However, Assenagon later sold a significant number of shares. TFX met expectations with Q1 earnings and revenues, and presented its results and 2024 outlook. They received a consensus PT of $252.50 from brokerages. Teleflex was also awarded a contract for Short Term Central Venous Catheters by Vizient. Innovations have been seen with the launch of Urolift 2 and adoption of o9’s AI-Powered Platform for business planning and supply chain management. The company also expanded into Canada with the launch of Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet. Yet, investors' profits over the past three years have been impacted negatively. The acquisition of Palette Life Sciences was completed and TFX announced another intent to acquire Vascular Solutions.
Teleflex Incorporated TFX News Analytics from Fri, 02 Dec 2016 08:00:00 GMT to Wed, 22 Jan 2025 02:33:57 GMT -
Rating 1
- Innovation 6
- Information 8
- Rumor 0
